We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Antipsicóticos atípicos y su papel en el desarrollo de enfermedades metabólicas.
- Authors
Ocando, Leynis; Roa, Alexander; León, Marian; González, Robys
- Abstract
Metabolic disorders associated with patients with schizophrenia go unnoticed in the largest proportion of cases due to many factors that are unknown to this condition. This may contribute to increase in morbidity and mortality. Patients with schizophrenia may have an increased risk of developing disorders in glucose and insulin metabolism, lipid abnormalities, and weight gain. Atypical antipsychotics in the treatment of this pathology provide various benefits and can reduce risk factors for morbidity and mortality. Conversely, the use of said drugs has been associated with metabolic comorbidities including metabolic syndrome, which might lead to serious complications, including cardiovascular disease. Recent consensus guidelines recommend considering metabolic risks at the moment of initiating atypical antipsychotics treatment. Therefore, initial screening and routine control of the weight of the patient, fasting lipid profile and fasting blood glucose are essential. Furthermore, ideal treatment for schizophrenic patients that also have a metabolic comorbidity requires a multi-disciplinary team (formed by a mental health caregiver, the patient and their family) that is able to work together and develop excellent communication skills. With due conscience and cooperation on the part of the medical community, caregivers and patients, the harmful consequences that can result from the metabolic disorders addressed in this article can be improved at least partially.
- Publication
Revista Latinoamericana de Hipertension, 2018, Vol 13, Issue 2, p98
- ISSN
1856-4550
- Publication type
Article